Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 13, 2024 6:29pm
115 Views
Post# 36223251

RE:RE:On la Presse

RE:RE:On la PresseI've resolved myself to the fact that the game changer in TH-1902 is no longer on the table.  I'll hold my investment in hopes for a buyout, opportunity to add a new drug, some miraculous new finding that does work, whatever, but my investment is now sunk cost that is unrecoverable based on where the company is at today.  I don't foresee any positive news coming out of TH-1902 within the next few months.  I think these guys had a reason to be excited with those pre-clinicals, but all of that has been destroyed in human testing.

Trogarzon wrote: It's good in the way it reinstates that the sales trend seem Ok for now.  It's paid advertisement.  What I dislike is the fact that our game changer th1902 is almost being downplayed here.  Also they highlight the importance of IQ and the fact that they are the biggest shareholder now.  Not exactly my friends for the  25 cents dilution.  Anyway it's up today.  My ACB is 16$ so I'll take a couple of them.


<< Previous
Bullboard Posts
Next >>